AmyriAD to Present Clinical and Preclinical Data at the 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference
LOS ANGELES, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AmyriAD Therapeutics, a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer’s disease, today announced that it will host a key opinion leader (KOL) webinar, entitled, “Looking Beyond Amyloid for Alzheimer’s Disease: Combination Therapy, a Strategy Long Overdue,” to take place virtually on Friday, September 30, 2022 at 11:15 AM Eastern Daylight Time.